65
Participants
Start Date
December 7, 2019
Primary Completion Date
September 12, 2022
Study Completion Date
January 30, 2023
lerodalcibep
PCSK9 inhibitor
evolocumab
PCSK9 inhibitor
Carbohydrate and Lipid Metabolism Research Unit, Johannesburg
Division of Lipidology, Department of Medicine University of Cape Town, Cape Town
Department of Medicine, Hadassah University Hospital, Jerusalem
Ege University Medical School, Izmir
Metabolic & Atherosclerosis Research Center (MARC), Cincinnati
Rabin Medical Center, Beilinson Hospital,, Petah Tikva
NorthShore University Health System, Evanston
G.B. Pant Institute of Postgraduate Medical Education & Research, New Delhi
VMMC & Safdarjung Hospital, Delhi
CIMS Hospital Pvt. Ltd, Ahmedabad
Afyonkarahisar Health Sciences University, Afyonkarahisar
Lipid Clinic, Oslo University Hospital, Oslo
Lead Sponsor
LIB Therapeutics LLC
INDUSTRY